Holdings
VanEck Biotech ETF
As of Jun 30, 2026, VanEck Biotech ETF reported 23 positions worth US$388M. Largest: Amgen Inc., Gilead Sciences, Inc. and Vertex Pharmaceuticals Incorporated. What it bought and sold, with each filing.
| Company | Shares | Value as reported | Change | As of |
|---|---|---|---|---|
| Amgen Inc. | 167K | US$60.3M | +12,986 | Jun 30, 2026 |
| Gilead Sciences, Inc. | 400K | US$50.6M | +10,246 | Jun 30, 2026 |
| Vertex Pharmaceuticals Incorporated | 72,485 | US$36M | +5,432 | Jun 30, 2026 |
| Regeneron Pharmaceuticals, Inc. | 39,388 | US$24.6M | +3,256 | Jun 30, 2026 |
| Revolution Medicines, Inc. | 111K | US$20.9M | +2,016 | Jun 30, 2026 |
| Argenx Se | 21,198 | US$19.7M | −5,654 | Jun 30, 2026 |
| Natera, Inc. | 71,677 | US$19.5M | −2,254 | Jun 30, 2026 |
| Iqvia Holdings, Inc. | 88,160 | US$17M | −5,491 | Jun 30, 2026 |
| Alnylam Pharmaceuticals, Inc. | 50,358 | US$15.2M | +4,238 | Jun 30, 2026 |
| Biogen Inc. | 66,394 | US$14.3M | −9,049 | Jun 30, 2026 |